Accepted for Publication: March 17, 2021.
Published Online: October 14, 2021. doi:10.1001/jamaoncol.2021.3595
Corresponding Author: Giuseppe Curigliano, MD, PhD, Division of Early Drug Development–European Institute of Oncology IRCCS, Via Ripamonti 435, Milan, Italy, 20141 (giuseppe.curigliano@ieo.it).
Author Contributions: Dr Tarantino had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Andrè and Curigliano contributed equally to the work.
Concept and design: Tarantino, Hamilton, Curigliano.
Acquisition, analysis, or interpretation of data: Modi, Tolaney, Cortés, Kim, Toi, Andrè, Curigliano.
Drafting of the manuscript: Tarantino, Hamilton, Curigliano.
Critical revision of the manuscript for important intellectual content: Tarantino, Modi, Tolaney, Cortés, Kim, Toi, Andrè, Curigliano.
Administrative, technical, or material support: Modi, Hamilton, Curigliano.
Supervision: Tarantino, Tolaney, Cortés, Curigliano.
Conflict of Interest Disclosures: Dr Modi reported receiving research funding and speaking/consulting fees from Genentech, Daiichi Sankyo, AstraZeneca, and Seattle Genetics, and consulting fees from MacroGenics during the conduct of the study. Dr Tolaney reported receiving grants from AstraZeneca, Bristol Myers Squibb, Cyclacel Pharmaceuticals, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead studies, Merck, NanoString, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics to the institution outside the submitted work; she also reported receiving honoraria for consultant or advisory board service from AstraZeneca, Athenex, Bristol Myers Squibb, Certara, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceuticals, Merck, Mersana Therapeutics, NanoString, Nektar, Novartis, Odonate, OncoPep, Pfizer, Puma Biotechnology, Samsung Bioepis, Sanofi, and Seattle Genetics. Dr Cortés reported receiving honoraria for consulting from Daiichi Sankyo and AstraZeneca during the conduct of the study; honoraria for consulting from Roche, Celgene, Cellestia, Bio-Thera, Merus, Seattle Genetics, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Novartis, Eisai, Pfizer, Samsung Bioepis, and Kyowa Kyrin outside the submitted work; and holding stock in MedSIR. Dr Hamilton reported research funding to the institution from OncoMed Research, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millennium Pharmaceuticals, Medivation, Acerta Pharma, Sermonix, Aravive, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, Fujifilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova, Dana-Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, Seagen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, StemCentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, AbbVie, NuCana, Leap Therapeutics, Zenith, Harpoon, Orinove, AstraZeneca, Tesaro, MacroGenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxicon, and Amgen; advisory fees paid to the institution from Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, and AstraZeneca outside the submitted work. Dr Kim reported receiving research funding to the institution from Novartis and Sanofi Genzyme. Dr Toi reported receiving grants from Chugai; lecture honoraria and grants from Daiichi Sankyo; and lecture and advisory honoraria for drug development during the conduct of the study; grants and lecture honoraria from Takeda, Pfizer, Kyowa Kirin, and Taiho; grants from the JBCRG Association, Eisai, AstraZeneca, and Eli Lilly; honoraria for lecture and as an advisor for drug development from Exact Sciences; honoraria for lecture from Novartis; grants from Astellas; honoraria as an advisor for drug development from Bristol Myers Squibb; grants and lecture honoraria from Shimadzu Yakult and Nippon Kayaku; grants from AFI Technologies; honoraria as an advisor from Athenex Oncology; honoraria as an advisor for drug development from Bertis; honoraria as an advisor for device development from Terumo; grants for device development from Luxonus; grants from Shionogi Research and GL Sciences; honoraria for an advisory role from Kansai Medical Net outside the submitted work; and honoraria for serving on the board of directors for JBCRG Association, Kyoto Breast Cancer Research Network, and Organisation for Oncology and Translational Research. Dr Andre reported receiving grants to the institution from Novartis, Roche, Pfizer, AstraZeneca, Daiichi Sankyo, and Lilly outside the submitted work. Dr Curigliano reported receiving honoraria for lectures and serving on the Daiichi Sankyo advisory board, grants from Merck for investigator-initiated research, and serving on the advisory boards of AstraZeneca, Bristol Myers Squibb, Roche, Lilly, Pfizer, Novartis, Exact Sciences, and Seagen outside the submitted work. No other disclosures were reported.
6.Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.
N Engl J Med. Published online September 18, 2021. doi:
10.1056/NEJMoa2112431 8.Siena
S , Di Bartolomeo
M , Raghav
KPS ,
et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 [abstract].
J Clin Oncol. 2020;38(15)(suppl):4000. doi:
10.1200/JCO.2020.38.15_suppl.4000Google Scholar 9.Sheng
X , Yan
X , Wang
L ,
et al. Open-label, multicenter, phase II study of RC48-ADC, a
HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma.
Clin Cancer Res. 2021;27(1):43-51. doi:
10.1158/1078-0432.CCR-20-2488
PubMedGoogle ScholarCrossref 11.Banerji
U , van Herpen
CML , Saura
C ,
et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and
HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol. 2019;20(8):1124-1135. doi:
10.1016/S1470-2045(19)30328-6
PubMedGoogle ScholarCrossref 12.Yamaguchi
K , Bang
Y-J , Iwasa
S ,
et al. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study [abstract].
Ann Oncol. 2020;31(suppl 4):S899-S900. doi:
10.1016/j.annonc.2020.08.1928Google ScholarCrossref 13.Powell
C , Camidge
D , Gemma
A ,
et al. Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: analysis of data available from multiple studies of DS-8201a, a HER2-targeted ADC with a topoisomerase I inhibitor payload. San Antonio Breast Cancer Symposium; December 4-8, 2018;
https://sabcs18.posterview.com/nosl/p/P6-17-06 15.Powell
CA , Camidge
DR , Modi
S ,
et al: 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies.
Ann Oncol 31(suppl 4):S357-S358, 2020. doi:
10.1016/j.annonc.2020.08.391Google ScholarCrossref 16.Geyer
CE , Untch
M , Prat
A ,
et al. Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual, invasive, early breast cancer after neoadjuvant therapy: a randomized phase 3 trial (DESTINY-Breast05) [abstract].
Cancer Res. 2021;81(suppl 4):OT-03-OT-01.
Google Scholar 20.Tamiya
A , Naito
T , Miura
S ,
et al. Interstitial lung disease associated with docetaxel in patients with advanced non–small cell lung cancer.
Anticancer Res. 2012;32(3):1103-1106.
PubMedGoogle Scholar 23.Mazzotta
M , Giusti
R , Iacono
D , Lauro
S , Marchetti
P . Pulmonary fibrosis after pegylated liposomal doxorubicin in elderly patient with cutaneous angiosarcoma.
Case Rep Oncol Med. 2016;2016:8034832. doi:
10.1155/2016/8034832
PubMedGoogle Scholar 24.Yoshii
N , Suzuki
T , Nagashima
M , Kon
A , Kakihata
K , Gemma
A . Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
Anticancer Drugs. 2011;22(6):563-568. doi:
10.1097/CAD.0b013e3283473f28
PubMedGoogle ScholarCrossref 25.Willemsen
AECAB , Grutters
JC , Gerritsen
WR , van Erp
NP , van Herpen
CM , Tol
J . mTOR inhibitor–induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm.
Int J Cancer. 2016;138(10):2312-2321. doi:
10.1002/ijc.29887
PubMedGoogle ScholarCrossref 28.Raschi
E , Fusaroli
M , Ardizzoni
A ,
et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Breast Cancer Res Treat. 2021;186(1):219-227. doi:
10.1007/s10549-020-06001-w
PubMedGoogle ScholarCrossref 33.Kumagai
K , Aida
T , Tsuchiya
Y , Kishino
Y , Kai
K , Mori
K . Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Cancer Sci. 2020;111(12):4636-4645. doi:
10.1111/cas.14686
PubMedGoogle ScholarCrossref 34.Press
MF , Cordon-Cardo
C , Slamon
DJ . Expression of the
HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Oncogene. 1990;5(7):953-962.
PubMedGoogle Scholar 35.Spira
A , Lisberg
A , Sands
J ,
et al. Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01phase 1 study.
J Thorac Oncol. 2021;16(suppl 3):S106-S107. doi:
10.1016/j.jtho.2021.01.280Google ScholarCrossref 37.Emens
LA , Esteva
FJ , Beresford
M ,
et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated,
HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol. 2020;21(10):1283-1295. doi:
10.1016/S1470-2045(20)30465-4
PubMedGoogle ScholarCrossref 38.Modi
S , Saura
C , Yamashita
T ,
et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer [abstract].
Cancer Res. 2021;81(suppl 4):PD3-PD06.
Google Scholar 39.Cortes J, Kim S-B, Chung W-P, et al. LBA1—trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study.
Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:
10.1016/annonc/annonc741 40.Hamilton
EP , Shapiro
C , Petrylak
D ,
et al. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study.
Cancer Res. 2021;81(suppl 4):PD3-PD07.
Google Scholar 41.Saura C, O’Shaughnessy J, Aftimos P, et al. LBA15—primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer.
Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:
10.1016/annonc/annonc741 42.Powell
CA , Camidge
DR , Modi
S ,
et al. Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies [abstract].
Ann Oncol. 2020;31(suppl 4):289P. doi:
10.1016/j.annonc.2020.08.391Google ScholarCrossref 43.Kubo
K , Azuma
A , Kanazawa
M ,
et al; Japanese Respiratory Society Committee for Formulation of Consensus Statement for the Diagnosis and Treatment of Dug-induced Lung Injuries. Consensus statement for the diagnosis and treatment of drug-induced lung injuries.
Respir Investig. 2013;51(4):260-277. doi:
10.1016/j.resinv.2013.09.001
PubMedGoogle ScholarCrossref 45.Struyf
T , Deeks
JJ , Dinnes
J ,
et al; Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.
Cochrane Database Syst Rev. 2020;7:CD013665.
PubMedGoogle Scholar 47.Jee
AS , Adelstein
S , Bleasel
J ,
et al. Role of autoantibodies in the diagnosis of connective-tissue disease ILD (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF).
J Clin Med. 2017;6(5):51. doi:
10.3390/jcm6050051
PubMedGoogle ScholarCrossref 48.Yamakawa
H , Hagiwara
E , Kitamura
H ,
et al. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.
J Thorac Dis. 2017;9(2):362-371. doi:
10.21037/jtd.2017.02.48
PubMedGoogle ScholarCrossref 57.Haanen
JBAG , Carbonnel
F , Robert
C ,
et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2017;28(suppl_4):iv119-iv142. doi:
10.1093/annonc/mdx225
PubMedGoogle ScholarCrossref 58.Brahmer
JR , Lacchetti
C , Schneider
BJ ,
et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol. 2018;36(17):1714-1768. doi:
10.1200/JCO.2017.77.6385
PubMedGoogle ScholarCrossref 61.ESMO. Primary outcomes of the multi-center multinational randomized phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice combination chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer. ESMO 2021; September 18, 2021; virtual meeting. Accessed September 14, 2021.
https://www.esmo.org/meetings/esmo-congress-2021/press-media 63.Moore
H , Shofer
S , Guisinger
A ,
et al. Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan—a retrospective review.
Cancer Res. 2021;81(suppl 4):PS13-PS33.
Google Scholar 68.Prophylactic inhaled steroids to reduce radiation pneumonitis frequency and severity in lung cancer patients. ClinicalTrials.gov identifier: NCT03803787. Updated February 10, 2021. Accessed March 1, 2021.
https://clinicaltrials.gov/ct2/show/NCT03803787 69.Infliximab and intravenous immunoglobulin therapy in treating patients with steroid-refractory pneumonitis. ClinicalTrials.gov identifier: NCT04438382. Updated August 20, 2021. Accessed March 1, 2021.
https://clinicaltrials.gov/ct2/show/NCT04438382